{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:53:42Z","timestamp":1783475622861,"version":"3.55.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:00:00Z","timestamp":1661558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"National Statement on Ethical Conduct in Human Research","award":["HREC\/17\/MH\/423"],"award-info":[{"award-number":["HREC\/17\/MH\/423"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Mucosal healing improves clinical outcomes in patients with inflammatory bowel disease (IBD) and is associated with higher infliximab trough levels (ITLs). Transmural healing, assessed by intestinal ultrasound (IUS), is emerging as an objective target in Crohn\u2019s disease (CD) and ulcerative colitis (UC). This study explores the correlation between maintenance ITLs and sonographic transmural healing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients on maintenance infliximab therapy were prospectively enrolled to undergo paired IUS examination and serum ITL. Infliximab trough levels were compared between patients with and without sonographic markers of inflammation using the Mann-Whitney U test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A prospective cohort of 103 patients (51% male; 79 CD; 24 UC; median duration of disease 8 years) underwent IUS and serum ITL testing. Forty-one percent of CD and 66% of UC patients demonstrated sonographic healing (bowel wall thickening \u22643 mm with no increase in color Doppler signal). Crohn\u2019s disease patients with sonographic healing had higher median ITL compared with those with sonographic inflammation (4.8 \u03bcg\/mL vs 3.1 \u03bcg\/mL; P = .049). Additionally, the presence of hyperemia on Doppler was independently associated with lower ITL compared with those without hyperemia (2.1 \u03bcg\/mL vs 4.2 \u03bcg\/mL, respectively; P = .003). There was no significant association between ITL and other sonographic markers of inflammation. In UC, lower ITL was associated with hyperemia on Doppler imaging (P = .04). There was no association between ITL and sonographic healing or any other individual sonographic parameter of inflammation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Lower maintenance infliximab levels are associated with sonographic parameters of inflammation in UC and CD. Further studies are needed to determine whether targeting higher infliximab levels can increase sonographic healing.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ibd\/izac186","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T15:30:08Z","timestamp":1662996608000},"page":"1080-1088","source":"Crossref","is-referenced-by-count":15,"title":["Infliximab Trough Levels Are Associated With Transmural Sonographic Healing in Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7534-1203","authenticated-orcid":false,"given":"Rose","family":"Vaughan","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The Royal Melbourne Hospital , Melbourne , Australia"},{"name":"Department of Medicine, The University of Melbourne , Melbourne , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Royal Melbourne Hospital , Melbourne , Australia"},{"name":"Pharmacy, The Royal Melbourne Hospital , Melbourne , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Nalder","sequence":"additional","affiliation":[{"name":"Pharmacy, The Royal Melbourne Hospital , Melbourne , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N","family":"Gibson","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Royal Melbourne Hospital and The University of Melbourne , Melbourne , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6952-0985","authenticated-orcid":false,"given":"Zaid","family":"Ardalan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Royal Melbourne Hospital , Melbourne , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Boussioutas","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Royal Melbourne Hospital , Melbourne , Australia"},{"name":"Department of Medicine, The University of Melbourne , Melbourne , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8746-4275","authenticated-orcid":false,"given":"Britt","family":"Christensen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Royal Melbourne Hospital , Melbourne , Australia"},{"name":"Department of Medicine, The University of Melbourne , Melbourne , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,27]]},"reference":[{"issue":"4","key":"2023070506311697400_CIT0001","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/ibd\/izx100","article-title":"Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part I","volume":"24","author":"Knowles","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2023070506311697400_CIT0002","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025.","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nature Reviews Gastroenterology &Amp Hepatology"},{"issue":"1","key":"2023070506311697400_CIT0003","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/gutjnl-2013-304984","article-title":"Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn\u2019s disease in the SONIC trial","volume":"63","author":"Peyrin-Biroulet","year":"2014","journal-title":"Gut"},{"issue":"11","key":"2023070506311697400_CIT0004","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.cgh.2019.11.056","article-title":"Histologic healing is more strongly associated with clinical outcomes in ileal Crohn\u2019s disease than endoscopic healing","volume":"18","author":"Christensen","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"9","key":"2023070506311697400_CIT0005","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol."},{"issue":"9","key":"2023070506311697400_CIT0006","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ibd.20927","article-title":"Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn\u2019s disease","volume":"15","author":"Schnitzler","year":"2009","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2023070506311697400_CIT0007","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2009.09.056","article-title":"Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn\u2019s disease","volume":"138","author":"Baert","year":"2010","journal-title":"Gastroenterology"},{"issue":"4","key":"2023070506311697400_CIT0008","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/j.cgh.2021.03.030","article-title":"Ultrasonography tight control and monitoring in Crohn\u2019s disease during different biological therapies: a multicenter study.","volume":"20","author":"Calabrese","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023070506311697400_CIT0009","first-page":"1","article-title":"Relevance of monitoring transmural disease activity in patients with Crohn\u2019s disease: current status and future perspectives.","volume":"14","author":"Wilkens","year":"2021","journal-title":"Therap"},{"key":"2023070506311697400_CIT0010","first-page":"S1542","article-title":"Predictive value of bowel ultrasound in Crohn\u2019s disease: a 12-month prospective study","volume":"Apr 22","author":"Allocca","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"8","key":"2023070506311697400_CIT0011","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/apt.16288","article-title":"Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn\u2019s disease","volume":"53","author":"Goodsall","year":"2021","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4","key":"2023070506311697400_CIT0012","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/ecco-jcc\/jjab173","article-title":"Defining transabdominal Intestinal Ultrasound treatment response and remission in inflammatory bowel disease: systematic review and expert consensus statement","volume":"16","author":"Ilvemark","year":"2021","journal-title":"J Crohn\u2019s and Colitis."},{"issue":"3","key":"2023070506311697400_CIT0013","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.cgh.2019.05.029","article-title":"Monitoring a combination of calprotectin and infliximab identifies patients with mucosal healing of Crohn\u2019s disease","volume":"18","author":"Dreesen","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2023070506311697400_CIT0014","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"},{"issue":"5","key":"2023070506311697400_CIT0015","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00535-017-1324-3","article-title":"Systematic review with meta-analysis: loss of response and requirement of anti-TNF\u03b1 dose intensification in Crohn\u2019s disease","volume":"52","author":"Qiu","year":"2017","journal-title":"J Gastroenterol."},{"issue":"2","key":"2023070506311697400_CIT0016","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/ecco-jcc\/jjy155","article-title":"Infliximab trough levels are associated with mucosal healing during maintenance treatment with infliximab in paediatric Crohn\u2019s disease","volume":"13","author":"Kang","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"4","key":"2023070506311697400_CIT0017","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cgh.2015.10.025","article-title":"Optimizing anti-TNF-alpha therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases","volume":"14","author":"Ungar","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"7","key":"2023070506311697400_CIT0018","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"2023070506311697400_CIT0019","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.cgh.2014.09.031","article-title":"Factors associated with short- and long-term outcomes of therapy for Crohn\u2019s disease","volume":"13","author":"Reinisch","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"2","key":"2023070506311697400_CIT0020","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/ibd\/izz131","article-title":"Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease","volume":"26","author":"Fernandes","year":"2020","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2023070506311697400_CIT0021","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12876-021-01650-7","article-title":"High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study","volume":"21","author":"Wilson","year":"2021","journal-title":"BMC Gastroenterol."},{"issue":"5","key":"2023070506311697400_CIT0022","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) Initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"2023070506311697400_CIT0023","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/apt.16232","article-title":"Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn\u2019s disease","volume":"53","author":"Lafeuille","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"issue":"9","key":"2023070506311697400_CIT0024","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1097\/MIB.0000000000001173","article-title":"Noninvasive fecal immunochemical testing and fecal calprotectin predict mucosal healing in inflammatory bowel disease: a prospective cohort study","volume":"23","author":"Ma","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"8","key":"2023070506311697400_CIT0025","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S2468-1253(18)30161-4","article-title":"Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn\u2019s disease (METRIC): a multicentre trial","volume":"3","author":"Taylor","year":"2018","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"5","key":"2023070506311697400_CIT0026","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cgh.2020.04.052","article-title":"Infliximab exposure associates with radiologic evidence of healing in patients with Crohn\u2019s disease","volume":"19","author":"Bossuyt","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"8","key":"2023070506311697400_CIT0027","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.dld.2019.02.013","article-title":"Infliximab therapy intensification upon loss of response: is there an optimal trough level?","volume":"51","author":"Ungar","year":"2019","journal-title":"Dig Liver Dis."},{"issue":"10","key":"2023070506311697400_CIT0028","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/ibd\/izaa219","article-title":"Terminal ileum thickness during maintenance therapy is a predictive marker of the outcome of infliximab therapy in Crohn disease","volume":"26","author":"Albshesh","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2023070506311697400_CIT0029","doi-asserted-by":"crossref","first-page":"i462","DOI":"10.1093\/ecco-jcc\/jjab232.626","article-title":"P499 Accessing ultrasonographic transmural healing in patients with Crohn\u2019s disease after induction therapy with infliximab: should we aim for higher infliximab trough levels?","volume":"16","author":"Mor\u00e3o","year":"2022","journal-title":"Journal of Crohn\u2019s and Colitis."},{"issue":"6","key":"2023070506311697400_CIT0030","first-page":"1435","article-title":"Biologic concentration testing in inflammatory bowel disease","volume":"21","author":"Vaughn","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"2023070506311697400_CIT0031","doi-asserted-by":"crossref","first-page":"S046","DOI":"10.1093\/ecco-jcc\/jjz203.049","article-title":"DOP10 intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn\u2019s disease: week 16 interim analysis of the STARDUST trial substudy","volume":"14","author":"Kucharzik","year":"2020","journal-title":"Journal of Crohn\u2019s and Colitis."},{"issue":"9","key":"2023070506311697400_CIT0032","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1007\/s10620-019-05567-w","article-title":"Clinical impact of sonographic transmural healing after anti-TNF antibody treatment in patients with Crohn\u2019s disease","volume":"64","author":"Paredes","year":"2019","journal-title":"Dig Dis Sci."},{"issue":"5","key":"2023070506311697400_CIT0033","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.dld.2017.02.014","article-title":"Cross-sectional evaluation of transmural healing in patients with Crohn\u2019s disease on maintenance treatment with anti-TNF alpha agents","volume":"49","author":"Castiglione","year":"2017","journal-title":"Dig Liver Dis."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izac186\/45799841\/izac186.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/7\/1080\/50693928\/izac186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/7\/1080\/50693928\/izac186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T21:20:55Z","timestamp":1701033655000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/29\/7\/1080\/6696163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,27]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,8,27]]},"published-print":{"date-parts":[[2023,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izac186","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2022,8,27]]}}}